杭州高光制药

Highlight Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. The company focuses on developing highly selective kinase inhibitors, with a particular emphasis on the Janus kinase (JAK) and Tyrosine kinase 2 (TYK2) pathways. Its lead candidate, TLL-018, is a potent dual TYK2/JAK1 inhibitor currently undergoing Phase 2 and Phase 3 clinical trials for indications such as rheumatoid arthritis and psoriasis. Highlight Pharmaceutical's pipeline also includes CNS-penetrant inhibitors designed to address neuro-inflammatory conditions. By leveraging its proprietary drug discovery platform, the company aims to provide next-generation treatments with improved safety and efficacy profiles compared to existing therapies. The firm is backed by prominent investors including HighLight Capital and Matrix Partners China.